ATE522603T1 - Löslicher komplex, der retrovirale oberflächen- glykoproteine und fkpa oder slyd enthält - Google Patents

Löslicher komplex, der retrovirale oberflächen- glykoproteine und fkpa oder slyd enthält

Info

Publication number
ATE522603T1
ATE522603T1 AT02758265T AT02758265T ATE522603T1 AT E522603 T1 ATE522603 T1 AT E522603T1 AT 02758265 T AT02758265 T AT 02758265T AT 02758265 T AT02758265 T AT 02758265T AT E522603 T1 ATE522603 T1 AT E522603T1
Authority
AT
Austria
Prior art keywords
hiv
chaperone
slyd
fkpa
retroviral surface
Prior art date
Application number
AT02758265T
Other languages
English (en)
Inventor
Christian Scholz
Herbert Andres
Elke Faatz
Alfred Engel
Dorothea Sizmann
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE522603T1 publication Critical patent/ATE522603T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
AT02758265T 2001-06-22 2002-06-24 Löslicher komplex, der retrovirale oberflächen- glykoproteine und fkpa oder slyd enthält ATE522603T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01115225 2001-06-22
EP01120939 2001-08-31
PCT/EP2002/006956 WO2003000877A2 (en) 2001-06-22 2002-06-24 A soluble complex comprising a retroviral surface glycoprotein

Publications (1)

Publication Number Publication Date
ATE522603T1 true ATE522603T1 (de) 2011-09-15

Family

ID=26076626

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02758265T ATE522603T1 (de) 2001-06-22 2002-06-24 Löslicher komplex, der retrovirale oberflächen- glykoproteine und fkpa oder slyd enthält
AT02747428T ATE445016T1 (de) 2001-06-22 2002-06-24 Verwendung von fkbp-chaperons als expressionswerkzeug

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT02747428T ATE445016T1 (de) 2001-06-22 2002-06-24 Verwendung von fkbp-chaperons als expressionswerkzeug

Country Status (15)

Country Link
US (2) US7244819B2 (de)
EP (3) EP2267452B8 (de)
JP (6) JP4262594B2 (de)
KR (2) KR100611545B1 (de)
CN (1) CN100510068C (de)
AT (2) ATE522603T1 (de)
AU (2) AU2002317841A1 (de)
BR (1) BRPI0210598B8 (de)
CA (3) CA2449747C (de)
DE (1) DE60233942D1 (de)
DK (2) DK2267452T3 (de)
ES (3) ES2391623T3 (de)
MX (1) MXPA03011455A (de)
PL (2) PL218245B1 (de)
WO (2) WO2003000877A2 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100611545B1 (ko) * 2001-06-22 2006-08-10 에프. 호프만-라 로슈 아게 레트로바이러스 표면 당단백질을 함유하는 가용성 복합체
JP4168028B2 (ja) * 2002-06-25 2008-10-22 積水化学工業株式会社 発現ベクター、宿主、融合タンパク質、融合タンパク質の製造方法及びタンパク質の製造方法
AU2003283205A1 (en) * 2002-11-26 2004-06-18 Danmarks Fodevare- Og Veterinaerforskning Dendrimer conjugates for selective of protein aggregates
EP1621555A4 (de) * 2003-04-18 2006-08-02 Sekisui Chemical Co Ltd Immunogen, zusammensetzung zur immunologischen verwendung und verfahren zur herstellung von antikörpern unter deren verwendung
AU2005317828A1 (en) * 2004-12-23 2006-06-29 Novozymes Delta Limited Gene expression technique
CA2562738C (en) 2005-10-26 2011-07-12 F. Hoffmann-La Roche Ag Soluble rubella e1 envelope antigens
ATE527345T1 (de) * 2006-01-03 2011-10-15 Hoffmann La Roche Chimäres fusionsprotein mit überlegenen chaperon- und faltungsaktivitäten
WO2007084021A2 (en) * 2006-01-17 2007-07-26 Instituto De Medicina Molecular Compositions and methods for diagnosing hiv-2 infection
JP2009536958A (ja) 2006-05-11 2009-10-22 ベクトン・ディキンソン・アンド・カンパニー 細胞からのタンパク質抽出方法
GB0611405D0 (en) 2006-06-09 2006-07-19 Univ Belfast FKBP-L: A novel inhibitor of angiogenesis
DK2112158T3 (da) 2007-04-20 2012-01-23 Hoffmann La Roche Påvisning af primære infektioner med patogener
US20100210827A1 (en) * 2007-09-06 2010-08-19 Nutrex Technology Co., Ltd. Preparation Method Of Recombinant Protein By Use Of A Fusion Expression Partner
US9207240B2 (en) 2007-11-14 2015-12-08 Arbor Vita Corporation Method of efficient extraction of protein from cells
EP2222694B1 (de) 2007-12-13 2014-01-15 Roche Diagnostics GmbH Neue varianten des rubella-e1-hüllproteins und ihre verwendung beim nachweis von anti-rubella-antikörpern
EP2127678A1 (de) 2008-05-26 2009-12-02 Roche Diagnostics GmbH SlpA als Werkzeug für recombinante Protein-und Enzym-technologie
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
EP2670847B1 (de) * 2011-02-03 2016-10-05 XOMA Technology Ltd. Verfahren und materialien zur verbesserten funktionellen proteinexpression bei bakterien
AR086250A1 (es) 2011-05-05 2013-11-27 Hoffmann La Roche Polipeptido de fusion presentador de una secuencia de aminoacidos y utilizacion del mismo
CA2832109C (en) 2011-06-10 2021-07-06 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
EP2568289A3 (de) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunselektion von rekombinantem vesikulärem Stomatitisvirus mit Expression von HIV-1-Proteinen durch Breitbandneutralisierungs-Antikörper
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
EP2617731A1 (de) 2012-01-19 2013-07-24 Roche Diagnostics GmbH Lösliche immunreaktive Treponem pallidum TpN47 Antigene
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
EP2706115A1 (de) 2012-09-06 2014-03-12 Roche Diagnostics GmbH Chaperon-Chaperon-Fusionspolypeptide zur Reduzierung der Störungen und Stabilisierung von Immunoassays
AU2013343667A1 (en) 2012-11-08 2015-04-02 F. Hoffmann-La Roche Ag HER3 antigen binding proteins binding to the beta-hairpin of HER3
MA38164B1 (fr) * 2012-11-08 2018-11-30 Hoffmann La Roche Protéines de liaison à l'antigène anti-her3/her4 se liant à la boucle en épingle à cheveux beta
US12540318B2 (en) * 2012-11-08 2026-02-03 Roche Diagnostics Operations, Inc. Nucleic acids encoding chimeric polypeptides for library screening
EP2827146A1 (de) 2013-07-18 2015-01-21 Roche Diagnostics GmbH Vibrio cholerae Lipoprotein 15 (Lp15)-Varianten als entstörende Zusätze bei TPN17-basierten Immunoassays zum Nachweis von Anti-Treponema-Antikörpern
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP3049437A1 (de) 2013-09-27 2016-08-03 F. Hoffmann-La Roche AG Thermus-thermophilus-slyd-fkbp-domänenspezifische antikörper
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP2913338A1 (de) 2014-02-28 2015-09-02 Roche Diagniostics GmbH Lösliche und immunoreaktive Varianten von HTLV-Antigen-Kapsid P24
JP2015215244A (ja) * 2014-05-12 2015-12-03 富士レビオ株式会社 免疫測定における抗ｈｔｌｖ抗体の検出感度を向上させる方法
MX2016014416A (es) 2014-05-14 2017-02-23 Hoffmann La Roche Anticuerpos anti-her3 que se unen a la horquilla beta de her3.
JP6695812B2 (ja) 2014-05-14 2020-05-20 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｈｅｒ３のベータヘアピン及びｈｅｒ２のドメインｉｉに結合するｈｅｒ３／ｈｅｒ２二重特異性抗体
CA2966358C (en) 2014-12-01 2021-12-07 Pfenex Inc. Fusion partners for peptide production
US20180023098A1 (en) * 2015-02-13 2018-01-25 Sekisui Chemical Co., Ltd. Nucleic acid, fusion protein, recombined cell, and isoprene or cyclic terpene production method
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
JP6967002B2 (ja) * 2015-12-15 2021-11-17 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft トランスグルタミナーゼ認識部位を有するｆｋｂｐドメイン
WO2017207599A1 (en) 2016-05-31 2017-12-07 Roche Diagnostics Gmbh Method for serological detection of viral antigens
KR102156994B1 (ko) 2016-05-31 2020-09-17 에프. 호프만-라 로슈 아게 Hcv 코어 항원의 신속한 검출을 위한 전처리 방법
WO2017220551A1 (en) * 2016-06-20 2017-12-28 Metgen Oy Method for obtaining active insoluble xylose isomerase
JP7068323B2 (ja) 2017-02-02 2022-05-16 エフ．ホフマン－ラ ロシュ アーゲー 少なくとも２種のペグ化された分析物特異的結合剤を使用する免疫アッセイ
CN110709410B (zh) 2017-04-26 2024-07-02 豪夫迈·罗氏有限公司 可溶性和免疫反应性寨卡病毒ns1多肽
EP3658171B1 (de) 2017-07-27 2023-08-30 Roche Diagnostics GmbH Multi-epitop-fusionsprotein eines hcv-antigens und verwendungen davon
CN110066343B (zh) * 2019-05-23 2021-04-09 北京新创生物工程有限公司 一种用于检测hiv新发感染的重组抗原及其应用
EP4139684A1 (de) 2020-04-23 2023-03-01 F. Hoffmann-La Roche AG Corona-nukleocapsid-antigen zur verwendung in antikörper-immuntests
WO2023012321A1 (en) 2021-08-06 2023-02-09 Roche Diagnostics Gmbh Chimeric igg-fc-binding ligand polypeptide and uses thereof for igg affinity purification
JP2025517121A (ja) 2022-05-03 2025-06-03 エフ． ホフマン－ラ ロシュ アーゲー 免疫診断アッセイのためのＨＩＶ ｇｐ４１バリアント
WO2025098623A1 (en) 2023-11-09 2025-05-15 Roche Diagnostics Gmbh Transglutaminase substrates for labeling

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2095818B (en) 1981-03-27 1985-10-02 Exxon Research Engineering Co Staged adsorption/resorption heat pump
US4735896A (en) 1986-03-04 1988-04-05 United Biomedical, Inc. Synthetic peptide and process of using same for the detection and diagnosis of AIDS and pre-AIDS conditions
US4879212A (en) 1986-04-02 1989-11-07 United Biomedical Inc. Peptide composition and method for the detection of antibodies to HTLV-III
US6024983A (en) 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
DE3705686C2 (de) 1987-02-23 1995-11-30 Boehringer Mannheim Gmbh Verfahren zur Bestimmung von Antikörpern
NZ224663A (en) 1987-05-28 1990-11-27 Amrad Corp Ltd Fusion proteins containing glutathione-s-transferase and expression of foreign polypeptides using glutathione-s-transferase encoding vectors
SE8704185L (sv) 1987-10-28 1989-04-29 Ferring Ab Nya peptider, artificiella antigener och immunoanalystestsatser
CA2003383A1 (en) * 1988-11-23 1990-05-23 Sushil G. Devare Synthetic dna derived recombinant hiv antigens
EP0602046B2 (de) 1991-06-14 2007-02-21 IDEXX Laboratories Inc Detektion des immunschwäche-virus aus felis
FI942907A7 (fi) * 1991-12-20 1994-06-17 Novo Nordisk As Menetelmä lipaasin valmistamiseksi
JP2001504572A (ja) 1992-04-09 2001-04-03 アボツト・ラボラトリーズ Ｈｉｖ抗原及びｈｉｖ抗体を検出するためのアッセイ
WO1993025533A1 (en) 1992-06-05 1993-12-23 Abbott Laboratories Methods and reagents for the determination of immunosuppressive agents
DK0663010T3 (da) * 1992-10-02 2000-11-13 Res Corp Technologies Inc Fremgangsmåde til forøgelse af sekretion af overudtrykte proteiner
US5459051A (en) 1993-03-26 1995-10-17 Celtrix Pharmaceuticals, Inc. Methods and vectors for over-expression of ubiquitin fusion proteins in host cells
DE4428705A1 (de) * 1994-08-12 1996-02-15 Boehringer Mannheim Gmbh Rekombinantes Antigen aus der NS3-Region des Hepatitis C Virus
WO1996012796A1 (en) 1994-10-25 1996-05-02 The Board Of Trustees Of The Leland Stanford Junior University Conditional transformation of genetically engineered cells
WO1996041865A1 (en) 1995-06-07 1996-12-27 Ariad Gene Therapeutics, Inc. Rapamcycin-based regulation of biological events
WO1997010502A1 (en) 1995-09-15 1997-03-20 Merck & Co., Inc. A high throughput assay using fusion proteins
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
GB9614114D0 (en) 1996-07-05 1996-09-04 Amcor Packaging Uk Ltd New packages
JP2001501093A (ja) 1996-09-26 2001-01-30 メディカル リサーチ カウンシル シャペロン断片
US6225082B1 (en) * 1997-05-09 2001-05-01 Research Corporation Technologies, Inc. Myelin basic protein MRNA transport and translation enhancer sequences
US5989868A (en) * 1997-09-12 1999-11-23 The Board Of Regents Of The University Of Oklahoma Fusion protein systems designed to increase soluble cytoplasmic expression of heterologous proteins in esherichia coli
EP1045915A2 (de) 1998-01-15 2000-10-25 Ariad Gene Therapeutics, Inc. Regulation biologischer vorgänge mittels chimärer multimerer proteinen
DE19913117A1 (de) * 1998-05-06 1999-11-11 Roche Diagnostics Gmbh Entstörung durch Rheumafaktoren
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
DE69836647D1 (de) 1998-10-02 2007-01-25 Vadeco Biotech Gmbh & Co Kg Methode zur herstellung von (poly)peptiden unter verwendung von verkürzten varianten von sv40 'large' t antigen mit einem intakten n terminus
CA2346962A1 (en) 1998-11-06 2000-05-18 President And Fellows Of Harvard College Fk506-based regulation of biological events
CA2364568A1 (en) 1999-03-17 2000-09-21 Adrian Woolfson Method for refolding molecules of polypeptides containing ig domains
CA2372199A1 (en) 1999-05-14 2000-11-23 Medical Research Council Oligomeric chaperone proteins
GB9913437D0 (en) 1999-06-09 1999-08-11 Medical Res Council Fusion proteins
EP1077263A1 (de) * 1999-07-29 2001-02-21 F.Hoffmann-La Roche Ag Verfahren zur Herstellung von natürlich gefalteten und sekretierten Proteinen durch Co-Sekretion von Chaperonen
CA2403718A1 (en) * 2000-03-17 2001-09-27 Panacos Pharmaceuticals, Inc. A method for generating immunogens that elicit neutralizing antibodies against fusion-active regions of hiv envelope proteins
JP2002262883A (ja) * 2001-03-13 2002-09-17 Sekisui Chem Co Ltd モノクローナル抗体の製造方法
KR100611545B1 (ko) * 2001-06-22 2006-08-10 에프. 호프만-라 로슈 아게 레트로바이러스 표면 당단백질을 함유하는 가용성 복합체

Also Published As

Publication number Publication date
ES2372031T3 (es) 2012-01-13
US20030096352A1 (en) 2003-05-22
KR100702373B1 (ko) 2007-04-02
EP2267452B1 (de) 2012-07-25
EP1402015B1 (de) 2011-08-31
CA2450476A1 (en) 2003-01-03
CN1524123A (zh) 2004-08-25
PL367679A1 (en) 2005-03-07
JP2009100770A (ja) 2009-05-14
CA2449747A1 (en) 2003-01-03
WO2003000877A2 (en) 2003-01-03
AU2002317841A1 (en) 2003-01-08
CA2770453A1 (en) 2003-01-03
EP1402041B1 (de) 2009-10-07
CA2450476C (en) 2012-05-15
CN100510068C (zh) 2009-07-08
MXPA03011455A (es) 2004-04-05
DE60233942D1 (de) 2009-11-19
JP2004534831A (ja) 2004-11-18
ES2391623T3 (es) 2012-11-28
KR100611545B1 (ko) 2006-08-10
DK2267452T3 (da) 2012-10-29
BRPI0210598B8 (pt) 2021-05-25
PL215170B1 (pl) 2013-10-31
DK1402015T3 (da) 2011-12-05
WO2003000878A2 (en) 2003-01-03
BR0210598A (pt) 2004-07-20
JP4174422B2 (ja) 2008-10-29
AU2002325265B2 (en) 2006-10-19
EP2267452B8 (de) 2012-11-14
US8426167B2 (en) 2013-04-23
PL218245B1 (pl) 2014-10-31
JP4262594B2 (ja) 2009-05-13
JP2007322436A (ja) 2007-12-13
ATE445016T1 (de) 2009-10-15
ES2333108T3 (es) 2010-02-17
EP1402015A2 (de) 2004-03-31
JP4320351B2 (ja) 2009-08-26
JP4309910B2 (ja) 2009-08-05
BRPI0210598B1 (pt) 2018-11-13
JP2009102320A (ja) 2009-05-14
KR20060027871A (ko) 2006-03-28
PL397776A1 (pl) 2012-07-16
WO2003000877A3 (en) 2003-10-30
CA2449747C (en) 2010-04-13
CA2770453C (en) 2014-12-09
KR20040010774A (ko) 2004-01-31
HK1068918A1 (zh) 2005-05-06
JP4523660B2 (ja) 2010-08-11
JP2007125026A (ja) 2007-05-24
US7244819B2 (en) 2007-07-17
WO2003000878A3 (en) 2003-10-09
EP1402041A2 (de) 2004-03-31
JP2004535195A (ja) 2004-11-25
EP2267452A1 (de) 2010-12-29
US20090028893A1 (en) 2009-01-29

Similar Documents

Publication Publication Date Title
ATE522603T1 (de) Löslicher komplex, der retrovirale oberflächen- glykoproteine und fkpa oder slyd enthält
EA200100943A1 (ru) Вич-пептиды, антигены, вакцинные композиции, набор для иммуноанализа и способ определения вич-индуцированных антител
EP1878742A3 (de) HIV-Peptide, -Antigene, -Impfstoffzusammensetzungen und -Immunoassay sowie Verfahren zur Erkennung von durch HIV induzierten Antikörpern
WO2002064615A3 (en) Monoclonal antibodies to human immunodeficiency virus and uses thereof
DE69833160D1 (de) Amplifizierung und Detektion von HIV-1 und/oder HIV-2
CY1112632T1 (el) Αναστολεις ασπαρτυλ πρωτεασης
AP1717A (en) Sulfonamide inhibitors of aspartyl protease.
TR200001553T2 (tr) HIV-1 Tat veya bunun türevleri.
EP1016671A3 (de) Menschliche, monoklonale Antikörper gegen das transmembrane Glycoprotein (gp41) des HIV-1, und verwandte Peptide
DZ3008A1 (fr) Inhibiteurs de l'aspartyle protéase.
DE69029937D1 (de) FÜr DIE CO4-BINDENDE DOMÄNE VON HIV SPEZIFISCHE ANTIKÖRPER
KR100725637B1 (en) Anti-HIV-1 vaccine comprising all or part of the HIV-1 Tat protein
EA200300335A1 (ru) Регуляторные и вспомогательные пептиды вич, антигены, вакцинные композиции, набор для иммуноанализа и способ обнаружения антител, индуцируемых вич
Marschang et al. HIV-I and HIV-2 isolates differ in their ability to activate the complement system on the surface of infected cells
SE8701628D0 (sv) Medel for analys mm
ES2058259T3 (es) Antigenos sinteticos para la deteccion de enfermedad relacionada con sida causada por lav-2.
WO2003052122A3 (en) Gp41 inhibitor
EP1546415A4 (de) Anti-tsg101-antikörper und ihre verwendungen bei der behandlung von virusinfektionen
DK1368478T3 (da) Polypeptid, der fremkalder HIV-neutraliserende antistoffer
Chen et al. A common immunological epitope existing between HIV-1 gp41 and human interferon-α and-β
Shokunbi et al. Incidence of antibodies to HIV₁ and HIV₂ gene products in seropositive cases seen in Ibadan, Nigeria
FR2874017B1 (fr) Peptides vih-1 modifies et leur utilisation en detection d'anticorps anti-vih
DK0494317T3 (da) SIV-cpz-ant-retrovirus og anvendelse deraf
DE68926454D1 (de) Gegen hiv 1 gp48 spezifische antikörper
DE69928275D1 (de) Verfahren zur bestimmung der prognose für hiv-infizierte individuen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1402015

Country of ref document: EP